chronic obstructive pulmonary disease
Conditions
Interventions
Hotyuekkito is administrated in patients with chronic obstructive pulmonary disease who receive pulmonary rehabilitation
Hotyuekkito is not administrated in patients with chronic obstructive pulmonary
Sponsors
Hiroshima University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)COPD stage 2-3, FEV1/FVC<70%,30%<FEV1 pred<70% 2)Clinically stable COPD 3)No reciving pulmonary rehabilitation within 24 weeks 4)Ideal body weight <100% 5)Age: 40 years or older 6)Smoking history > 10 pack-years 7)Male or female 8)Patients who will be able to receive treatment for 12 weeks 9)Written informed consent
Exclusion criteria
Exclusion criteria: 1)Diagnosed other pulmonary diseases 2)No acute exacervation within 4 weeks 3)Receiving pulmonary transplantation 4)Receiving herbal medicine within 4 weeks 5)Receiving inhaled or systemic steroid therapy within 2 weeks 6)Engage other clinical trial within 4 weeks 7)alpha1 antitrypsin deficiency 8)Severe other diseases such as malignancy, autoimmune disease, liver disease, renal disease, heart disease, hematologic disease, and metabolic disease 9)Pregnant and nursing 10)Inappropriate patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Six minutes walking test Safety | — |
Secondary
| Measure | Time frame |
|---|---|
| Grasping powergrip, Body weight, Body mass index, Hematological data, Modified Medical Research Council dyspnea scale, Quality of life questionnaire | — |
Countries
Japan
Contacts
Public ContactNoboru Hattori
Hiroshima University Hospital Department of Respiratory Medicine
Outcome results
None listed